BIOMAT Database Logo BIOMAT Database Logo

Heterogeneous expression of melanoma-associated antigens in uveal melanomas. 1987

J P van der Pol, and M J Jager, and D de Wolff-Rouendaal, and P J Ringens, and C Vennegoor, and D J Ruiter

Twenty-five uveal melanomas were stained with seven monoclonal antibodies (MoAbs) recognizing different antigens on cutaneous melanomas. A two step immuno-peroxidase procedure was used. Phenotypic heterogeneity was observed for four MoAbs (M.2.2.4, AMF-7, 225.28S, PAL-M1) while two MoAbs (NKI-beteb, CL203.4) reacted strongly with most (85%) uveal melanomas, and one MoAb (R-24) showed very low reactivity. Despite heterogeneity, co-expression of some antigens was observed. Expression of the antigen recognized by MoAb M.2.2.4. was significantly lowered by pre-enucleation irradiation while the other antigens remained unchanged. Expression of antigens on uveal melanomas differed markedly from primary cutaneous melanomas. The clinical relevance of these findings awaits further study.

UI MeSH Term Description Entries
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D011300 Preoperative Care Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed) Care, Preoperative,Preoperative Procedure,Preoperative Procedures,Procedure, Preoperative,Procedures, Preoperative
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D014604 Uveal Neoplasms Tumors or cancer of the UVEA. Neoplasm, Uveal,Neoplasms, Uveal,Uveal Neoplasm

Related Publications

J P van der Pol, and M J Jager, and D de Wolff-Rouendaal, and P J Ringens, and C Vennegoor, and D J Ruiter
Expression of HLA antigens in paraffin sections of uveal melanomas.
December 1986, Documenta ophthalmologica. Advances in ophthalmology,
J P van der Pol, and M J Jager, and D de Wolff-Rouendaal, and P J Ringens, and C Vennegoor, and D J Ruiter
Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.
February 1998, International journal of cancer,
J P van der Pol, and M J Jager, and D de Wolff-Rouendaal, and P J Ringens, and C Vennegoor, and D J Ruiter
Transporter associated protein expression in uveal melanoma.
July 2004, The British journal of ophthalmology,
J P van der Pol, and M J Jager, and D de Wolff-Rouendaal, and P J Ringens, and C Vennegoor, and D J Ruiter
p53 expression in uveal malignant melanomas.
November 1996, Pathology,
J P van der Pol, and M J Jager, and D de Wolff-Rouendaal, and P J Ringens, and C Vennegoor, and D J Ruiter
Expression of somatostatin receptors in uveal melanomas.
March 2003, Investigative ophthalmology & visual science,
J P van der Pol, and M J Jager, and D de Wolff-Rouendaal, and P J Ringens, and C Vennegoor, and D J Ruiter
Metastasis-associated microRNA expression in canine uveal melanoma.
March 2018, Veterinary and comparative oncology,
J P van der Pol, and M J Jager, and D de Wolff-Rouendaal, and P J Ringens, and C Vennegoor, and D J Ruiter
Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma.
June 1985, Cancer research,
J P van der Pol, and M J Jager, and D de Wolff-Rouendaal, and P J Ringens, and C Vennegoor, and D J Ruiter
Expression of classic and nonclassic HLA class I antigens in uveal melanoma.
May 2003, Investigative ophthalmology & visual science,
J P van der Pol, and M J Jager, and D de Wolff-Rouendaal, and P J Ringens, and C Vennegoor, and D J Ruiter
Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas.
June 2022, Ocular oncology and pathology,
J P van der Pol, and M J Jager, and D de Wolff-Rouendaal, and P J Ringens, and C Vennegoor, and D J Ruiter
Expression of melanoma-associated antigens in melanoma cell cultures.
July 2005, Experimental dermatology,
Copied contents to your clipboard!